samedan logo
home > ebr > spring 2021 > optimising technical transfers
European Biopharmaceutical Review

Optimising Technical Transfers

Technical transfers are a fact of life in pharmaceutical/ biopharmaceutical development. Whether a process is being scaled for commercialisation, transferred to another contract development and manufacturing organisation (CDMO), or reproduced at the same scale at an additional site, pitfalls exist at every step when attempting to replicate a production process.

Companies transferring a process must focus on three key factors: the equipment, the process, and the employees’ knowledge of the product. Obstacles to the smooth transfer differ, and some types of tech transfers are more complex than others. In this article, we discuss the challenges associated with tech transfers and share how Northway Biotech helps customers overcome such challenges at its twin facilities in Massachusetts (US) and Lithuania (Europe).

Tech Transfer Challenges

A technical transfer can replicate a single operation, a fully developed production process, or anything in between. Biotech companies may be seeking a CDMO with extra capacity to produce a particular drug substance or drug product, or they may need material on an accelerated timeline. Other companies wish to increase the volume they produce at another facility, or they want to consolidate workflow – for example, a company working with four different CDMOs may want to trim its list of partners.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Northway Biotech is a leading CDMO supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products.

The company's wide-ranging expertise and vertically integrated service offering the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania, London, UK, and in Waltham, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement